15 March 2016 | Statements

Unitaid report considers how to make essential medicines affordable

A new UNITAID study considers how to make essential medicines available and affordable to those in need.

Drawing examples from intellectual-property issues in the treatment of HIV, hepatitis C, tuberculosis and cancer, the authors recommend various options that governments can take to lower prices and increase access to essential medicines.

In May 2015, the World Health Organization (WHO) added several medicines – including some for the treatment of cancer, tuberculosis and hepatitis C – to its Model List of Essential Medicines. These new medicines, which are currently priced out of reach to most patients – present a key opportunity to use the List as a tool for access, argue the authors.

The World Trade Organization’s TRIPS agreement sets minimum standards for the protection of intellectual property rights – so members can no longer exclude entire fields of technology, such as medicines, from patentability. Innovative new medicines are increasingly patented around the world, and are thus available only at monopoly prices that prevent widespread access.

This paper suggests numerous options that governments could consider to counter this trend. Such options include:

“The recent shifts in the WHO Essential Medicines paradigm demand a bold approach to avoid unnecessary delays in making these medicines available to the populations in need,” write the authors.

LINK TO REPORT [PDF, 280 KB]

View All News

Featured News

21 February 2024

Unitaid-backed research underpins WHO recommendation for first-ever multidrug-resistant TB prevention regimen for children

Read More

02 February 2024

Need to improve oxygen access has not ended with the pandemic

Read More

Sign Up for Unitaid Updates

  • This field is for validation purposes and should be left unchanged.